GLP-1 receptor agonists in diabetic kidney disease

Erin D. Michos; Katherine R. Tuttle

doi:10.2215/CJN.18771220

GLP-1 receptor agonists in diabetic kidney disease

Erin D. Michos
, Katherine R. Tuttle

Research output: Contribution to journal › Comment/debate

21 Scopus citations

Original language	English
Pages (from-to)	1578-1580
Number of pages	3
Journal	Clinical Journal of the American Society of Nephrology
Volume	16
Issue number	10
DOIs	https://doi.org/10.2215/CJN.18771220
State	Published - Oct 2021

Access to Document

10.2215/CJN.18771220

Cite this

@article{0d4665d250344e47b434eb2a3956245b,

title = "GLP-1 receptor agonists in diabetic kidney disease",

author = "Michos, \{Erin D.\} and Tuttle, \{Katherine R.\}",

note = "Funding Information: K.R. Tuttle reports employment with Providence Health Care, University of Washington; consultancy agreements with AstraZe-neca, Bayer, Boehringer Ingelheim, Eli Lilly, Gilead, Goldfinch Bio, and Novo Nordisk; receiving research funding from Bayer and Goldfinch Bio; receiving honoraria from Bayer, Gilead, and Goldfinch Bio; and serving as a scientific advisor or member of CJASN, Kidney Health Initiative, Lancet Diabetes \& Endocrinology, Nature Reviews Nephrology, and the National Institute of Diabetes and Digestive and Kidney Diseases. The remaining author has nothing to disclose.",

year = "2021",

month = oct,

doi = "10.2215/CJN.18771220",

language = "English",

volume = "16",

pages = "1578--1580",

journal = "Clinical Journal of the American Society of Nephrology",

issn = "1555-9041",

publisher = "Lippincott Williams and Wilkins",

number = "10",

}

TY - JOUR

T1 - GLP-1 receptor agonists in diabetic kidney disease

AU - Michos, Erin D.

AU - Tuttle, Katherine R.

N1 - Funding Information: K.R. Tuttle reports employment with Providence Health Care, University of Washington; consultancy agreements with AstraZe-neca, Bayer, Boehringer Ingelheim, Eli Lilly, Gilead, Goldfinch Bio, and Novo Nordisk; receiving research funding from Bayer and Goldfinch Bio; receiving honoraria from Bayer, Gilead, and Goldfinch Bio; and serving as a scientific advisor or member of CJASN, Kidney Health Initiative, Lancet Diabetes & Endocrinology, Nature Reviews Nephrology, and the National Institute of Diabetes and Digestive and Kidney Diseases. The remaining author has nothing to disclose.

PY - 2021/10

Y1 - 2021/10

UR - https://www.scopus.com/pages/publications/85117125398

U2 - 10.2215/CJN.18771220

DO - 10.2215/CJN.18771220

M3 - Comment/debate

C2 - 33849933

AN - SCOPUS:85117125398

SN - 1555-9041

VL - 16

SP - 1578

EP - 1580

JO - Clinical Journal of the American Society of Nephrology

JF - Clinical Journal of the American Society of Nephrology

IS - 10

ER -

GLP-1 receptor agonists in diabetic kidney disease

Access to Document

Other files and links

Cite this